Metastatic Cancer Clinical Trial
Official title:
Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors
Verified date | November 2019 |
Source | Jonsson Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and the best dose of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor BMN-673 when given together with temozolomide or irinotecan hydrochloride in treating patients with locally advanced or metastatic solid tumors. PARP inhibitor BMN-673 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help temozolomide and irinotecan hydrochloride work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving PARP inhibitor BMN-673 with temozolomide or irinotecan hydrochloride may be an effective treatment for patients with advanced solid tumors.
Status | Completed |
Enrollment | 44 |
Est. completion date | October 7, 2019 |
Est. primary completion date | October 7, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor for which no standard therapy is recognized or for which standard therapy has failed - Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST, v1.1) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT may be =< 5 x ULN - Total serum bilirubin =< 1.5 x ULN - Calculated creatinine clearance of >= 40 ml/min; as per Cockcroft-Gault formula - Hemoglobin >= 9.0 g/dL - Absolute neutrophil count (ANC) >= 1500/mm^3 - Platelet count >= 100,000/mm^3 - Able to take oral medications - Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures - Sexually active patients must be willing to use an acceptable method of contraception such as double barrier contraception during treatment and for 30 days after the last dose of BMN 673 - Females of childbearing potential must have a negative serum pregnancy test at screening Exclusion Criteria: - Has not recovered (recovery is defined as National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE version (v)4.03] grade =< 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting the inclusion requirements stated in the inclusion criterion - Prior treatment with a PARP inhibitor - Prior allergic reaction or severe intolerance to either irinotecan or temozolomide - History of central nervous system (CNS) metastasis that are untreated or not stable - Any antitumor systemic cytotoxic therapies within 28 days prior to enrollment (6 weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excluded - Is known to have human immunodeficiency virus (HIV) or has active hepatitis C virus (HCV), or active hepatitis B virus (HBV) - Has had major surgery within 28 days prior to enrollment - Active gastrointestinal tract disease with malabsorption syndrome - Requirement for IV alimentation - Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) - Symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication (atrial fibrillation is permitted) - Use of any investigational product or investigational medical device within 28 days prior to enrollment - Concurrent disease or condition that would interfere with study participation or safety, such as: - Active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade > 2 by NCI CTCAE (v 4.03) within 14 days prior to enrollment - Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders - Non-healing wound, ulcer, or bone fracture - Bone marrow disorder including myelodysplasia |
Country | Name | City | State |
---|---|---|---|
United States | Jonsson Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Jonsson Comprehensive Cancer Center | BioMarin Pharmaceutical, Medivation, Inc., Translational Research in Oncology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Limiting Toxicity graded using the NCI CTCAE v. 4.03 | Up to 28 days | ||
Secondary | Incidence of adverse events graded by NCI CTCAE v. 4.03 | Characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy. | Up to 12 months | |
Secondary | Levels of PARP inhibitory BMN 673 | Baseline, at 30 and 60 minutes, at 1.5, 2, 3, 4, 6, and 8 hours of day 1 of courses 1 and 2 | ||
Secondary | levels of temozolomide | Baseline, at 30 and 60 minutes, at 1.5, 2, 3, 4, 6, and 8 hours of day 1 of courses 1 and 2 | ||
Secondary | Levels of irinotecan hydrochloride | Baseline, at 30 and 60 minutes, at 1.5, 2, 3, 4, 6, and 8 hours of day 1 of courses 1 and 2 | ||
Secondary | Biomarker levels in blood and tumor tissue | Baseline and Cycle1 Day 21 for participants undergoing biopsy (expansion phase only) | ||
Secondary | Incidence of laboratory abnormalities graded by NCI CTCAE v. 4.03 | Characterized by type, frequency, severity, timing, seriousness and relationship to study therapy. | Up to 12 months | |
Secondary | Objective tumor response assessed using RECIST v. 1.1 | Sum of partial responses plus complete responses. The proportion of ever achieving a clinical response will be estimated, and an exact one-sided 90% confidence interval will be constructed to identify the likely range for the underlying tumor response rate. | Up to 12 months | |
Secondary | Duration of response | The log rank test will be used to examine association between categorical markers and time to disease progression. Cox-proportional hazards regression models will be used to correlate quantitative markers with time to disease progression. | Time of initial response until documented tumor progression, assessed up to 12 months | |
Secondary | Progression-free survival | Time from enrollment until objective tumor progression or death, assessed up to 12 months | ||
Secondary | Overall survival (OS) | Time from randomization until death from any cause, up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
Not yet recruiting |
NCT03058809 -
Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |